Skip to content

S. 3311 · 118th Congress (2023–2025)

American Made Pharmaceuticals Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Show official title

A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 3311’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Tina Smith (D-MN)
Cosponsors
2 cosponsors

1 original · 1 later

  1. Sen. Tom Cotton (R-AR)· Original · Nov 15, 2023
  2. Sen. Michael F. Bennet (D-CO)· Later · Dec 6, 2023
Policy area
Health
Subjects
  • Buy American requirements
  • Child health
  • Congressional oversight
  • Drug therapy
  • Emergency medical services and trauma care
  • Health care costs and insurance
  • Health technology, devices, supplies
  • Infectious and parasitic diseases
  • 6 more
    • Manufacturing
    • Medicaid
    • Medicare
    • Poverty and welfare assistance
    • Prescription drugs
    • Public contracts and procurement

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Finance.

    Sources
  3. Expired

    Introduced → Referred to Senate committee → No further action before the 118th Congress ended.

Committees

  1. SenateBanking, Housing, and Urban AffairsHearings by (full committee) Jul 25, 2024
    1. Jul 25, 2024 · Meeting

  2. SenateFinanceReferred Nov 15, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. American Made Pharmaceuticals Act of 2023

    Display title, Short title · Introduced in Senate

  2. A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.

    Official title · Introduced in Senate